Jeff Ryckman, Associate Professor of Radiation Oncology at WVU Medicine Camden Clark Medical Center, shared on X:
“Improved MFS w/ darolutamide in DASL-HiCaP!
- 1,106 very high-risk prostate cancer pts, incl persistent/rising PSA after RP. Randomised to darolutamide vs placebo w/ ADT + RT.
- Median age 71; GS 9-10 73%; CT N+ 29%; prior RP 15%.
- 4y MFS on conventional imaging: 95% vs 88%, HR 0.42 (95% CI 0.27-0.66). No clear OS benefit yet.
- All prescribed prostate/bed AND pelvic nodal RT, w/ 96 wk ADT.
- N+ = CT/MRI >10 mm short axis or path confirmation (PSMA PET alone insufficient if ≤10 mm).
Side note: RT dose/fx and PSMA staging use aren’t reported in the abstract.”
You can also read:
DASL-HiCaP at ESMO 2026: Darolutamide Plus ADT and Radiotherapy in Very High-Risk Prostate Cancer
